Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
August 18 2022 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER
PURSUANT TO RULE 13a-16
OR 15d-16 OF THE
SECURITIES EXCHANGE ACT
OF 1934
For the month of August 2022
Commission File Number: 001-39446
CureVac N.V.
(Exact Name of Registrant as Specified in Its
Charter)
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
On August 18, 2022, CureVac N.V. (the “Company”)
issued a press release announcing the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, developed in collaboration
with GlaxoSmithKline (“GSK”). The vaccine candidate is based on the Company’s second-generation mRNA backbone and is
designed to specifically protect against the Omicron variant.
The information included in this Form 6-K (including
Exhibit 99.1, but excluding the statements of the Company’s Chief Development Officer contained in Exhibit 99.1 hereto) is
hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CUREVAC N.V. |
|
|
|
|
By: |
/s/ Franz-Werner Haas, LLD, LLM |
|
|
|
Chief Executive Officer |
Date: August 18, 2022
EXHIBIT INDEX
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
From Apr 2023 to Apr 2024